Abbott Laboratories — Jan 22, 2025 release

percent 1 – Full-year 2024 reported sales increased 4.6 percent; organic sales growth for the underlying base business increased 9.6 percent 2 – Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5% ABBOTT PARK, Ill., Jan. 22, 2025 — Abbott today announced financial results for the fourth quarter ended Dec. 31, 2024. • Fourth-quarter sales increased 7.2 percent on a reported basis, 8.8 percent on an organic basis, and 10.1 percent on an organic basis, excluding COVID-19 testing-related sales. • Fourth-quarter GAAP diluted EPS of $5.27 and adjusted diluted EPS of $1.34, which excludes specified items (refer to page 13 for a reconciliation of GAAP EPS to adjusted EPS). • Full-year 2024 sales of $42.0 billion increased 4.6 percent on a reported basis, 7.1 percent on an organic basis, and 9.6 percent on an organic basis, excluding COVID-19 testing-related sales. • Full-year 2024 gross margin as a percent of sales improved 60 basis points on a GAAP basis compared to 2023 and improved 70 basis points on an adjusted basis. • Full-year 2024 GAAP diluted EPS of $7.64 and adjusted diluted EPS of $4.67, which excludes specified items (refer to page 14 for a reconciliation of GAAP EPS to adjusted EPS). • For the full-year 2024, Abbott achieved the upper end of the initial guidance ranges the company provided in January 2024 for both organic sales growth and adjusted earnings per share. •